Literature DB >> 11144463

Numbers of IFN-gamma-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy.

T Ulrichs1, R Anding, S H Kaufmann, M E Munk.   

Abstract

ESAT-6 is a specific Mycobacterium tuberculosis complex antigen and strong inducer of interferon-gamma (IFN-gamma) production by T cells from tuberculosis patient T-cells. We studied the frequency of IFN-gamma producing cells reacting to ESAT-6 during anti-tuberculosis chemotherapy. The numbers of IFN-gamma producing cells in the peripheral blood were higher in tuberculosis patients after discharge from specific anti-tuberculosis chemotherapy, compared with untreated patients. These results indicate that monitoring specific M. tuberculosis antigen reactivity during anti-tuberculosis chemotherapy may avoid premature termination of treatment and resistant strains.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11144463

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


  15 in total

1.  Effect of chemotherapy on whole-blood cytokine responses to Mycobacterium tuberculosis antigens in a small cohort of patients with pulmonary tuberculosis.

Authors:  Sylvie Bertholet; David J Horne; Elsa M Laughlin; Margery Savlov; Ines Tucakovic; Rhea N Coler; Masahiro Narita; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-29

2.  Sensitivity of a whole-blood interferon-gamma assay among patients with pulmonary tuberculosis and variations in T-cell responses during anti-tuberculosis treatment.

Authors:  M Pai; R Joshi; M Bandyopadhyay; P Narang; S Dogra; B Taksande; S Kalantri
Journal:  Infection       Date:  2007-04       Impact factor: 3.553

3.  Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar.

Authors:  Niaina Rakotosamimanana; Vaomalala Raharimanga; Soa Fy Andriamandimby; Jean-Louis Soares; T Mark Doherty; Maherisoa Ratsitorahina; Herimanana Ramarokoto; Alimuddin Zumla; Jim Huggett; Graham Rook; Vincent Richard; Brigitte Gicquel; Voahangy Rasolofo-Razanamparany
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  Reversion and conversion of Mycobacterium tuberculosis IFN-gamma ELISpot results during anti-tuberculous treatment in HIV-infected children.

Authors:  Tom G Connell; Mary-Ann Davies; Christine Johannisen; Kathryn Wood; Sandy Pienaar; Katalin A Wilkinson; Robert J Wilkinson; Heather J Zar; David Beatty; Mark P Nicol; Nigel Curtis; Brian Eley
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

5.  Evaluation of T-cell responses to novel RD1- and RD2-encoded Mycobacterium tuberculosis gene products for specific detection of human tuberculosis infection.

Authors:  Xiao-Qing Liu; Davinder Dosanjh; Hansa Varia; Katie Ewer; Paul Cockle; Geoffrey Pasvol; Ajit Lalvani
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

6.  T-cell responses to CD1-presented lipid antigens in humans with Mycobacterium tuberculosis infection.

Authors:  Timo Ulrichs; D Branch Moody; Ethan Grant; Stefan H E Kaufmann; Steven A Porcelli
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

7.  Differential live Mycobacterium tuberculosis-, M. bovis BCG-, recombinant ESAT6-, and culture filtrate protein 10-induced immunity in tuberculosis.

Authors:  Zahra Hasan; Bushra Jamil; Mussarat Ashraf; Muniba Islam; Maqboola Dojki; Muhammad Irfan; Rabia Hussain
Journal:  Clin Vaccine Immunol       Date:  2009-05-13

8.  In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.

Authors:  Ilaria Sauzullo; Fabio Mengoni; Miriam Lichtner; Anna Paola Massetti; Raffaella Rossi; Marco Iannetta; Raffaella Marocco; Cosmo Del Borgo; Fabrizio Soscia; Vincenzo Vullo; Claudio Maria Mastroianni
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

9.  Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis'.

Authors:  Nawal Salahuddin; Farheen Ali; Zahra Hasan; Nisar Rao; Masooma Aqeel; Faisal Mahmood
Journal:  BMC Infect Dis       Date:  2013-01-19       Impact factor: 3.090

10.  ESAT6-induced IFNgamma and CXCL9 can differentiate severity of tuberculosis.

Authors:  Zahra Hasan; Bushra Jamil; Mussarat Ashraf; Muniba Islam; Muhammad S Yusuf; Javaid A Khan; Rabia Hussain
Journal:  PLoS One       Date:  2009-04-02       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.